Serenus.AI

Company Overview

Snapshot

Founded in March 2017 by Hillary (Orly) Harel, Dan Berachowitz, and Prof. Josef Elidan, Serenus.AI operates with 1-10 employees. The company has raised $2.7 million across two funding rounds from four investors. In May 2021, Serenus.AI was granted a US patent for its automated method and system for screening and prevention of unnecessary medical procedures.

Business overview

Serenus.AI develops advanced Generative AI technologies to enhance medical decision-making at critical junctures in patient pathways, aiming to save lives and resources. Its flagship product is a clinically objective, Generative AI-powered automated case-by-case system designed to improve decisions before medical procedures and treatments, while also prioritizing patient waiting lists. The system's algorithms replicate the objective decision-making processes of top physicians by integrating up-to-date medical practices, professional knowledge, and machine learning. Serenus.AI's solution is compatible with various health systems, including US insurance companies and public health systems, and is active in Europe and the United States, serving healthcare stakeholders.

Strategic signal

In May 2021, Serenus.AI secured a US patent for its automated method and system for screening and preventing unnecessary medical procedures. This patent underscores the company's innovative approach to leveraging AI in healthcare, providing a strong signal of its intellectual property strength and its potential to address a significant burden on healthcare systems by improving utilization and prior authorization processes.

Company Intelligence Q&A

What is Serenus.AI's core technology?

Serenus.AI specializes in Generative AI technologies that empower medical decisions and optimize patient pathways. Its system uses algorithms to replicate objective decision-making processes of top physicians, combining medical practices, professional knowledge, and machine learning.

When was Serenus.AI granted a key US patent?

In May 2021, Serenus.AI was granted a US patent for its automated method and system designed for screening and prevention of unnecessary medical procedures.

Which investors participated in Serenus.AI's Seed funding round?

In July 2018, Serenus.AI received Seed funding from investors including Firstime VC and thetime.

Has Serenus.AI formed any strategic partnerships?

In September 2020, Serenus.AI partnered with HealthTrio to launch AI Prior-Auth Connect, a platform aimed at streamlining and automating medical prior authorizations using AI technologies.

What is the total capital raised by Serenus.AI?

Serenus.AI has raised a total of $2.7 million across two funding rounds.